Certolizumab pegol: Difference between revisions
Jump to navigation
Jump to search
m (Protected "Certolizumab pegol": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
| Line 1: | Line 1: | ||
{{SI}} | {{SI}} | ||
| Line 18: | Line 18: | ||
{{humanizedmonoclonals}} | {{humanizedmonoclonals}} | ||
[[Category:Monoclonal antibodies]] | [[Category:Monoclonal antibodies]] | ||
Revision as of 23:41, 8 August 2012
Overview
Certolizumab pegol (CDP870) is a PEGylated Fab' fragment of a humanized anti-TNF-alpha monoclonal antibody.
It is the subject of phase III clinical trials in both Crohn's disease[1] and rheumatoid arthritis. [2]
Positive results have been demonstrated in two phase III trials (PRECiSE 1 and 2) of certolizumab pegol vs placebo in moderate to severe active Crohn's disease.
In addition, data from both trials suggest it is well-tolerated. As yet its efficacy has not been directly compared to other anti-TNF-alpha agents.
References
- ↑ Sandborn WJ, Feagan BG, Stoinov S; et al. (2007). "Certolizumab pegol for the treatment of Crohn's disease". N. Engl. J. Med. 357 (3): 228–38. doi:10.1056/NEJMoa067594. PMID 17634458.
- ↑ Kaushik VV, Moots RJ (2005). "CDP-870 (certolizumab) in rheumatoid arthritis". Expert opinion on biological therapy. 5 (4): 601–6. doi:10.1517/14712598.5.4.601. PMID 15934837.
External links
- certolizumab+pegol at the US National Library of Medicine Medical Subject Headings (MeSH)